A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
A phase 1/2 trial of Zalifrelimab and Balstilimab in prostate cancer, head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma, run by ImmunoGenesis, now recruiting.
Overview
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab is a phase 1/2 interventional study registered as NCT06782555 by ImmunoGenesis, with 71 participants planned, started 2025-01-08 and due to reach its primary completion in 2027-10. Interventions recorded: Evofosfamide, Zalifrelimab and Balstilimab.
Similar pages
not linked directly; found by shared links- TrialVorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Shares Balstilimab, Agenus and the tag pipeline.
- TrialA Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialStudy of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialPsilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
- TrialA Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.